As a prescriber of opioids, dentists play an important role in addressing the opioid epidemic. As part of a long-standing commitment to help curb opioid use disorder and overdose, Cigna has collaborated with dentists to increase awareness of:
For customers who have their dental, medical and pharmacy benefits through Cigna, this combined data plays a key role. Cigna is harnessing dental and pharmacy data and analytics to help drive prevention, early intervention, and create long-term solutions in collaboration with providers.
An analysis of three years of Cigna customers with dental and pharmacy benefits revealed a 19 percent reduction in opioid (morphine milligram equivalent) prescriptions and 9 percent reduction for opioid days’ supply across dental specialists in the Cigna network.1 These findings demonstrate that Cigna's dental providers are embracing the CDC’s recommendations [PDF] to help reduce opioid misuse, including to routinely prescribe NSAIDs for acute pain or prescribe opioids for three days or less to manage acute pain from dental procedures (e.g. wisdom tooth extraction, root canal, etc.).
“Analyzing integrated pharmacy and dental data is an important step in helping us understand patterns of opioid prescriptions among dental providers,” said Dr. David Hamlin, Regional Dental Director, Cigna. “Through the power of data, collaboration, and education, we can identify opportunities to help improve treatment, intervene early, and support dental providers and customers in new ways.”
The recent data analysis of existing claims is just the start of what can be achieved through data. In addition to sharing insights with the dental community, including at the 2019 annual International Association for Dental Research (IADR) conference, Cigna will continue to evaluate what drives opioid prescriptions for specific populations and build tools to monitor safety across a network of over 146,000 dental providers.2 Cigna is also exploring research and partnerships with technology companies to evaluate the role of digital pain management.
“We work closely with providers and give them the information, resources, and tools they need to help their patients manage pain in the safest way possible,” said Dr. Doug Nemecek, Chief Medical Officer for Behavioral Health, Cigna. “One opportunity is informing treatment plans through data-driven insights. This is true for both medical and dental pain management, and as a result we are reducing reliance on opioids – a win for patients, families, and communities.”
For more information about Cigna’s commitment to reducing opioid use and efforts to fight the opioid epidemic, please visit Cigna: Fighting the Opioid Epidemic. To learn more about Cigna's efforts to improve oral health visit Cigna Dental DNA.
The content provided in this article is for educational purposes only. It is not medical advice and is not a substitute for medical care provided by a physician. Any third party content is the responsibility of such third party. Cigna does not endorse or guarantee the accuracy of any third party content and is not responsible for such content. Your access to and use of this content is at your sole risk.
Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require use an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and complete details of prescription drug coverage, contact a Cigna representative.
All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Cigna Behavioral Health, Inc., Cigna Health Management, Inc., Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.
© 2020 Cigna. All rights reserved